Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR6002 vs Co-administration of BR6002A and BR6002B
NCT05959486Phase 1Completed
- Sponsor
- Boryung
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lafutidine + irsogladine maleate in gastric ulcer and duodenal ulcer (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Concentration-time Curve Over the Dosing Interval and Maximum Plasma Concentration. Started Jul 2023; status: completed.
02
Drugs
lafutidine + irsogladine maleate
03
Conditions
gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on NCT05959486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959486.